What if you'd held CHRS?
A $1,000 investment in Coherus Oncology, Inc. (CHRS) at the month-end close of 2014-11 would be worth $96.87 at the close of 2026-08 — -90.3% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $3,728.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2014
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2014 | $1,000 | — |
| 2015 | $1,407 | +40.7% |
| 2016 | $1,725 | +22.6% |
| 2017 | $539 | -68.7% |
| 2018 | $555 | +2.8% |
| 2019 | $1,103 | +99.0% |
| 2020 | $1,065 | -3.5% |
| 2021 | $978 | -8.2% |
| 2022 | $485 | -50.4% |
| 2023 | $204 | -58.0% |
| 2024 | $84.56 | -58.6% |
| 2025 | $87.01 | +2.9% |
| 2026 | $81.50 | -6.3% |
Best and worst month-end to buy
The best single month-end close to have bought CHRS was 2025-06 ($0.73): $1,000 then is $1,819 today. The worst was 2015-07 ($35.08): $1,000 then is $37.91.
FAQ
What would $1,000 in CHRS be worth today?
A $1,000 investment in Coherus Oncology, Inc. (CHRS) at the start of 2014 would be worth about $96.87 today, a total return of -90.3%. Dividends are reinvested in these figures.
What were the best and worst years for CHRS?
Coherus Oncology, Inc. (CHRS)'s strongest calendar year since 2014 was 2019, a +99.0% return — $1,000 held through that year became about $1,990 by year-end. Its weakest year was 2017, at -68.7%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in CHRS have grown?
Investing $100 at the end of every month since 2014-11 would have grown to about $4,466 on $14,200 invested.
Did CHRS beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $3,728. CHRS trailed the S&P 500 by +97.4% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Coherus Oncology, Inc. (CHRS) historical total-return data from 2014-11 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.